MARKHAM, ON, Oct. 17, 2017 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, welcomes and supports the clarity provided by the Staff Notice issued by the Toronto Stock Exchange ("TSX") on October 16, 2017 which the Company believes levels the playing field for listed cannabis issuers in Canada.
Since its listing, MedReleaf has been and continues to operate with the goal of being at all times fully compliant with the TSX requirements pursuant to Sections 306, Section 325, and Part VII (collectively the "Requirements") in the TSX Company Manual and is confident that the review and enforcement of the Staff Notice will have no impact on its operations or listing on the TSX.
"The TSX Staff Notice removes the uncertainty for issuers that were already adhering to the Requirements and validates our strategy of focusing on markets that are federally legal and offer federal regulatory guidelines," said Neil Closner, CEO of MedReleaf. "Until there is further clarity on the U.S. market at the federal level, we will focus on growth areas within Canada and elsewhere in the world that have federal regulations in place, minimizing risk to the business and our shareholders."
About MedReleaf Corp.
MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf
Forward Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for MedReleaf to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in MedReleaf's Annual Information Form dated June 27, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in MedReleaf's Annual Information Form could cause actual events or results to differ materially from those described in any forward-looking information.
SOURCE MedReleaf Corp.
For further information: Contact Information: Dennis Fong, Investor Relations, firstname.lastname@example.org , 416-283-9930